Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Sunday, November 1, 2026

Back to the front page

From X

@kevin__mak

Kevin Mak on X

I think this is a good analysis and I'm long $QURE, but I want to flag something about this style of argument because it shows up across a lot of stocks. The common version is "the fundamentals are much better than they were x years ago, but the market cap is the same, so it must be underpriced." That doesn't follow. A disconnect like that means one of the two prices was wrong. It could be too cheap now, or it could have been too expensive before. All you actually know is that the market was probably wrong once. (To credit: @ClearPath100 doesn't explicitly say it's underpriced here.) That said, I still think these situations are worth finding. I generally assume the market is more often right than wrong, so a stock that moves with its fundamentals isn't very interesting. The disconnects are where the market might be wrong, and that's what we want. You just have to do the work to figure out which price was the wrong one. For QURE, I think the shorter comparison is more useful than the 5 year one. The stock was $70+ before the FDA denial that took it to $8. It's $48 today at a lower market cap than it was at $70. In between, the path to approval got better, not worse. The BLA is filed, the confirmatory study design is agreed, the timeline to commercialization is shorter, there's a year more of follow up data, and more cash on the balance sheet. Every risk that exists today also existed at $70. The biggest risk that did exist at $70, the FDA refusing the dataset, has already played out and been resolved. So which price was wrong? My guess is a lot of sharp people owned this at $70+, dumped it on the news, and never came back. I think they were right to sell back then. But if you were right to own it at $75 with more risks and a longer timeline, you should want to own it even more at $48 with fewer risks and a shorter one. Not buying it back isn't consistent with their own original view. I think the reason is simple. Losing 75% on a stock stings, and it's a lot easier to stay away than to admit the same thesis is back on the table at a better price. That's part of why we own it here. Disclosure: Creek Drive and its affiliated funds holds a long position in QURE. Views expressed are current opinions for informational educational only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in my bio for more important information.

Investor Letters

All letters

Altria: Dutiful

Altria raised 2026 adjusted EPS guidance to $5.66 to $5.74 and authorized more buybacks, while on! loses share as cigarette margins hold.

MO $130B
Invariant 3 clicks

When the liquidity does not add up

Arbor Realty Trust’s dividend suspension is presented as creating $60 million of liquidity, raising questions about its ability to meet…

ABR $2.2B
John Hempton's Newsletter 4 clicks

Verra veerer

Verra Mobility’s Avis termination threatens 2027 earnings, while Government Solutions profit rose 25% and implied fourth-quarter guidance…

VRRM $333M
The Oak Bloke 3 clicks

FTAI 3Q26: Aero margins in focus

FTAI’s Aerospace Products margin rebounded to 31% as CFM56 module output rose, while Power deposits and contracted deliveries fund its 2027…

FTAI $17B
Stock Thoughts 5 clicks
T · short

At&t INC

AT&T’s stalled deleveraging and share repurchase case has prompted a bearish turn on the telecom stock.

T $149B
Value Investors Club

CVX Earnings Review

Chevron’s Q3 revenue rose 35% to $65.2 billion and EBITDA 75% to $20.2 billion, while production trailed guidance and refining margins…

CVX $423B
Cestrian Capital Research 4 clicks

SNY Earnings Review

Sanofi raised FY26 guidance after Q3 sales grew 14.3% at constant currency, led by 34.8% Dupixent growth; vaccines declined 6.6%.

SNY $114B
Cestrian Capital Research 1 click

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 74 of 277

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.